Publications by authors named "Lizmery S Ferguson"
Programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) are immunomodulatory molecules overexpressed in lymphomas and are promising immunotherapy targets for hematologic malignancies. However, studies of PD-1/PD-L1 overexpression and their clinical significance in aggressive pediatric non-Hodgkin lymphomas (NHL) are limited. We assessed PD-1/PD-L1 overexpression using immunohistochemistry in 68 aggressive pediatric NHL: ALK-positive anaplastic large cell lymphoma (ALK+ ALCL, n=8), Burkitt lymphoma (BL, n=27), and large B-cell lymphoma (LBCL) de novo LBCL, n=22 and diffuse LBCL arising as monomorphic post-transplant lymphoproliferative disorder [PTLD-DLBCL], n=11.
View Article and Find Full Text PDFMyeloid sarcoma (MS) is a neoplastic condition composed of immature myeloid cells involving an extramedullary site. We investigated underlying chromosomal and molecular alterations to assess potential molecular markers of prognosis and outcome in this rare pediatric disease. We conducted a retrospective review of clinicopathologic and cytogenetic data from 33 pediatric patients with MS (ages 1 month-18 years) at our institution over a 32 year period (1984-2016).
View Article and Find Full Text PDFArticle Synopsis
- BRAF p.V600E mutations are present in over 50% of pediatric LCH cases, and the effectiveness of using specific BRAF V600E IHC as a substitute for traditional molecular testing is being evaluated.
- In a study of 26 pediatric LCH samples, the BRAF VE1 IHC showed a sensitivity of 100% but a low specificity of 18.2% when lenient scoring was used, while stringent criteria improved specificity to 100% but lowered sensitivity to 80%.
- The findings suggest that while molecular testing remains the gold standard, clear BRAF VE1 staining with specific intensity and percentage is critical for accurate diagnosis, especially in cases where the tissue is minimal or decalcified.